# Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults

> **NCT00094705** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 28 (actual)

## Conditions studied

- Dengue Fever

## Interventions

- **BIOLOGICAL:** rDEN2/4delta30(ME) Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00094705
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2008-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094705, "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00094705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*